Kornimate/medical-research-clean huggingface dataset:
thyroid dysfunction and obstetric complications

Conditions: Pregnancy

Summary: obstetric complications are common and can be responsible for maternal and foetal morbidity and mortality. thyroid dysfunction has been identified as a possible cause of obstetric complications. many studies have been conducted to estimate the prevalence and define the nature of obstetric complications observed in patients with thyroid dysfunction. however, women with obstetric complications are not systematically screened for thyroid dysfunction and no published study has evaluated the prevalence of thyroid dysfunction in women with an obstetric complication. as no consensus has been reached concerning systematic screening for thyroid dysfunction in pregnant women, the identification of new high-risk populations could possibly result in a change of clinical practice.


Eligibility criteria:
inclusion criteria: women attending the emergency room and/or hospitalised or followed for: * spontaneous and/or repeated miscarriage * foetal death * pre-eclampsia * retroplacental haematoma * post-partum haemorrhage * premature delivery * who consent to participate in the study. * assessment of these women will include blood samples for a laboratory work-up and anti-thyroid antibodies. exclusion criteria: * normal pregnancy

Keywords: thyroid dysfunction obstetric complications
support, training, and education for pain self-management using podcasts: a pilot trial

Conditions: Chronic Pain

Summary: this randomized stage 1 pilot trial tests the feasibility of a community health worker (chw) delivered chronic pain self-management intervention for older adults ("step-up"; support, training, and education for pain self-management - using podcasts) in a primary care setting. a total of 40 participants aged 50+ with high-impact chronic pain will be randomized to intervention or control groups. the step-up intervention will feature an educational podcast series teaching core pain self-management skills. podcasts will be supplemented by sessions with a community health worker taking place at designated times over a 7-week period. the community health worker will guide participants in a modified patient priorities of care approach to help them identify their values and priorities and develop goals that reflect these.


Eligibility criteria:
inclusion criteria: * age \> 50 years * have a mobile or landline phone * report high-impact chronic musculoskeletal pain (defined as pain in muscles or joints for \> 3 months "most days" or "every day" on a scale of never, some days, most days, or every day) and their pain limited life or work activities over the past 3 months "most days" or "every day" * have not participated in another chronic pain self-management intervention in the last 5 years. * able to converse comfortably in english exclusion criteria: * serious acute illness or hospitalization in the last month; * planned major surgery in the next three months that would interfere with program participation (e.g., knee or hip replacement) * severe cognitive impairment or other severe physical or psychiatric disorder judged by the study team to pose a significant barrier to participation
neurogenic lower urinary tract symptoms in patients with multiple sclerosis

Conditions: Multiple Sclerosis; Neurogenic Bladder

Summary: there is no consensus in the literature upon the neurourological diagnostic algorithm of the patients with multiple sclerosis (ms). the primary aim of the study is phenotyping the patients with ms. these phenotypes might guide neurology and urology specialists during diagnosis and treatment. secondary aim of this study is to define the presence and severity of urological symptoms' and disorders', involving the patients with diagnosis of ms less than 5 years into a urological follow-up and treatment process. our study might include 4 visits (the first visit, 3rd month, 6th month and 12th month visit). questionnaires, uroflowmetry and bladder diary might be repeated on each visit. filling cystometry and pressure-flow study will be performed only on the first visit. all patients will receive 6 different questionnaires which aim to define the severity and presence of lower urinary tract symptoms. bladder diary is an online application which will represent at least 3 days of frequency, urgency, incontinence episodes and the amount of fluid intake, and urination. the phenotypes would be defined after performing the first visit diagnostic tools (all of the tools are necessary during the diagnostic algorithm of neurogenic lower urinary tract symptoms). the phenotypes will be defined as: a. no symptoms with normal urodynamics, b. lower urinary tract symptoms with normal urodynamics, c. no symptoms with abnormal urodynamics, d.lower urinary tract symptoms with abnormal urodynamics. during a follow-up period of 1 year, changes in the bladder diaries and scores in questionnaires of these groups will be compared on each visit.


Eligibility criteria:
inclusion criteria: the patients who are followed up by department of neurology with ms diagnosis less than 5 years exclusion criteria: 1. patients who are not eligible for completing questionnaires, bladder diaries. 2. patients who have anatomical disorders preventing lithotomy position during urodynamic study. 3. patients in relapsing period of ms 4. patients who have symptoms of urinary tract infection
extension study of maintenance treatment with subcutaneous immunoglobulin (igpro20) for chronic inflammatory demyelinating polyneuropathy (cidp)

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Summary: this study is an extension study to the pivotal study igpro20_3003 (nct01545076). the purpose of this extension study is to investigate the long-term treatment of cidp with igpro20, with regard to safety and efficacy. subjects who have completed subcutaneous (sc) week 25 or were successfully rescued from a cidp relapse during the sc treatment period of pivotal study igpro20_3003 (nct01545076) will have the option to receive open-label low-dose igpro20 (0.2 g/kg bodyweight \[bw\]) weekly for up to 48 weeks. subjects relapsing on low-dose igpro20 will either return to high-dose igpro20 (0.4 g/kg) immediately or be discontinued, depending on investigator's judgment. subjects returning to high-dose igpro20 will continue on high-dose until they have completed a total of 48 weeks of igpro20 treatment. if subjects do not successfully recover from cidp relapse within 4 weeks, they will be withdrawn. the treatment duration will be up to 48 weeks, followed by a completion visit (week 49).


Eligibility criteria:
inclusion criteria: * subjects having completed the pivotal study igpro20_3003 (sc week 25) or successfully rescued from a cidp relapse during the sc treatment period of pivotal study igpro20_3003 (nct01545076). * written informed consent for study participation obtained before undergoing any study-specific procedures. exclusion criteria: * subject is unable to directly transition from study igpro20_3003. * new medical condition and/or social behavior (ie, alcohol, drug, or medication abuse) during participation in study igpro20_3003 that in the judgment of the investigator could increase risk to the subject, interfere with the evaluation of investigational medicinal product, and/or conduct of the study.
bay-43-9006 in advanced, metastatic soft tissue sarcomas

Conditions: Sarcoma, Soft Tissue

Summary: the aim of this study (\*) is to evaluate the progression free survival rate at 6 months, response rate, overall disease control rate, overall survival of bay-43-9006 in soft tissue sarcoma patients. (\*) as per protocol amendment no. 1 of 16 april 2007 approved by local iec on 24 july 2007


Eligibility criteria:
inclusion criteria: * histologically documented, progressive, advanced or metastatic sarcoma after adjuvant and/or first line anthracycline-based regimen; age \>=18 yrs; ecog ps =2; at least 1 measurable target lesion; life expectancy \>=12 wks; adequate medullary liver and renal function; written informed consent. exclusion criteria: * metastatic brain disease; pregnant or breast-feeding patients; serious infections.
the effects of gyngerlean supplementation on energy expenditure

Conditions: No Disease or Condition is Being Studied; Metabolism

Summary: the goal of this randomized controlled study is to asses the effects of a ginger containing supplement on energy expenditure and substrate utilization in healthy men. the main questions it aims to answer are" * the effects of kaempferia parviflora extract on energy expenditure * the effects of kaempferia parviflora extract on substrate utilization


Eligibility criteria:
inclusion criteria: * active adults. active is defined as exercising 3 or more times a week for 30 minutes. exclusion criteria: * participants must not be diabetics, have celiac disease, or individuals with pre-existing heart or kidney disease.
compliance of long-term home non-invasive ventilation for patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: background : long-term home non-invasive ventilation (niv) can be proposed as treatment for acute respiratory failure with severe alveolar hypoventilation. the aim of niv is to correct both daytime and night-time hypoventilation and associated symptoms and to provide the patient with adequate night-time oxygen saturation. the benefits of long-term niv in the management of chronic obstructive pulmonary disease (copd) patients in a stable state remain controversial. this highlights the importance of identifying the predictive factors for good compliance to the niv, defined as a use of more than 4 hours per day. aim of the study: the main objective is this observational study is to monitor the home niv compliance over a period of 1 year under real conditions of treatment in patients with copd newly initiated onto niv (with telemonitoring or not) in order to specify the predictive criteria for good compliance. the secondary objectives are to assess the evolution of functional respiratory data, niv parameters and changes in prescription, occurrence of acute exacerbations of copd, hospitalizations and death, patient outcomes (quality of life and acceptability of niv). study design: a cohort of 120 patients with copd newly initiated onto home-niv (with telemonitoring or not), either in a stable state or following an acute exacerbation will be enrolled in the study and follow-up over 1 year. data will be collected by lung specialists and home health care provider teams at 1-month post-initiation of niv, 6 months and 1 year. the study is conduct in france.


Eligibility criteria:
inclusion criteria: * copd patients who require the initiation of a home-niv (in case of previous equipment: niv interrupted for more than 6 months). * life expectancy greater than 1 year. * patient who has agreed to participate in the observational study after receiving clear information from the investigator and signing the consent form. exclusion criteria: * niv indicated for the treatment of chronic respiratory failure other than copd. * patient with overlap syndrome (copd associated to osa). * patient with limitations who do not allow proper use of the niv device. * simultaneous participation in a health intervention research.

Keywords: home non-invasive ventilation compliance quality of life exacerbation
effectiveness of polymyxin b sulphate + prednisolone + benzocaine + clioquinol in acute and sub-acute dermatitis eczematous

Conditions: Eczema

Summary: dermatitis eczematous is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions. the purpose of this trial is evaluate the effectiveness of two different topic associations of drugs.

study design: * experiment duration: 22 days * 2 visits (days 0,7,15 and 22) * reducing eczema area and severity index evaluation * adverse events evaluation * double blinded, non-inferiority, prospective parallel-group, intend to treat trial.

Eligibility criteria:
inclusion criteria: 1. patients must be able to understand the study procedures agree to participate and give written consent. 2. patients with acute or subacute dermatitis with a minimum of 3 symptoms. exclusion criteria: 1. pregnancy or risk of pregnancy. 2. lactation 3. use of anti-inflammatory or immunosuppressive drugs (last 30 days prior to the study). 4. sunlight over exposure in the last 15 days. 5. any pathology or past medical condition that can interfere with this protocol.

Keywords: dermatitis dermatitis, atopic
evaluation of the role of poisoning severity score, serum procalcitonin and c-reactive protein in acute hydrocarbon intoxicated cases admitted to the poison control center ain shams university hospitals

Conditions: Acute Hydrocarbon Toxicity

Summary: hydrocarbons are a primary energy source in modern society. they are present in many common household and occupational products, including motor fuels, paint thinners, cleaning agents, lotions, and industrial solvents. unfortunately, these products are also used as agents of abuse and typically inhaled . they are derived mainly from petroleum (kerosene, gas, naphtha) or wood (turpentine, pine oil). they can be found in liquid, gas, or solid form depending on their properties. all hydrocarbons can be toxic, but aromatic (ring-shaped) and halogenated hydrocarbons typically have more severe toxicity . toxicity occurs in various ways including through inhalation, ingestion, aspiration, and dermal exposure. frequently, these exposures occur during attempted recreational use of the substances and sometimes for self-injurious behavior


Eligibility criteria:
inclusion criteria: patients of both sexes admitted to the poison control center, ain shams university hospitals with acute hydrocarbon toxicity during the duration from december 2023 till december 2024 with a maximum number of 60 cases within 24 hours of intoxication. exclusion criteria: patients with these criteria will be excluded: * cases \> 24 hours of intoxication. * cases with occupational exposure to hydrocarbons. * pregnant females. * any cases received any treatment before arrival to the pcc. * cases suffering from cardiac, respiratory, renal, hepatic or haematological disorders. * cases presenting with fever. * cases with other causes that can increase levels of crp \& pro-calcitonin as bacterial infection, recent major trauma, major burn ,septic shock and medullary thyroid cancer.
effect of phototherapy on serum calcium

Conditions: Phototherapy; Side Effects

Summary: through this study our aim was to evaluate whether significant change in serum calcium level occurs in term newborns who are undergoing phototherapy and to find out the association between effect of phototherapy on serum calcium level and birth weight, postnatal age and type of feeding.

jaundice is the yellow discoloration of skin, sclerae, and other tissues caused by the deposition of bilirubin. approximately 60% of term and 80% of preterm babies develop jaundice in the first week of life, and about 10% of breastfed babies are still jaundiced at 1 month. jaundice is a common cause of readmission to hospital after early discharge of newborn infants. the most common form of hyperbilirubinaemia observed in neonates is due to unconjugated or unbound bilirubin. high levels of unconjugated bilirubin are managed by treatment of the underlying cause (e.g. dehydration and sepsis), provision of phototherapy, administration of immunoglobulin (in certain cases of haemolytic anaemia) and, in very severe cases, exchange transfusion. if left untreated, extreme elevation of unconjugated bilirubin can lead to permanent brain damage (kernicterus) and/or death. however, exchange transfusion is associated with a significant morbidity, and even mortality while phototherapy has several disadvantages which include increasing the duration of hospitalization, costs and mother-child separation . it also has some reported side effects as rash, loose green stools, dehydration, ocular hazards, oxidative injury, hyperthermia and water loss and may be associated with some long-term side effects such as melanocytic nevi, skin cancer, allergic disease, patent ductus arterious and retinal damage . some studies are available concerning the prevalence of hypocalcemia in neonates after phototherapy, but the results varied based on where the studies were conducted. so, more studies were required to reach a definite conclusion. through this study our aim was to evaluate whether significant change in serum calcium level occurs in term newborns who are undergoing phototherapy and to find out the association between effect of phototherapy on serum calcium level and birth weight, postnatal age and type of feeding.

Eligibility criteria:
inclusion criteria: * stable term neonates with jaundice who require management with phototherapy and are fed with full strength formula or breast fed. exclusion criteria: * jaundiced neonates with hypocalcemia. * jaundiced neonates needing exchange transfusion. * jaundiced neonates suffering from hypothyroidism. * jaundiced infants of diabetic mother. * jaundiced infants with other illness as severe rds, perinatal asphyxia,sever sepsis or hemolytic disease of newborn. * jaundiced infants with congenital abnormalities.

Keywords: phototherapy hypocalcemia
sodium-restricted diet and diuretic in the treatment of severe sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: this study evaluates the intervention of the 1) sodium-restricted diet, or 2) diuretic, or 3) placebo pill in the treatment of obstructive sleep apnea in adults.

men with apnea-hypopnea index greater than 30/hour will be included and randomly assigned into three groups: sodium-restricted diet, or diuretic, or control. the intervention will last one week. the diuretic group will receive combined spironolactone 100mg plus furosemide 20mg daily. the diet group will receive a regimen with a maximum intake of three grams of sodium per day. the control group will receive a placebo pill and will maintain all eating habits.

Eligibility criteria:
inclusion criteria: * men in the age range from 18 to 60 years * full-night in-laboratory polysomnography with apnea-hypopnea index \> 30/h in the last three months * body mass index \< 35 kg/m2 * informed consent exclusion criteria: * already having started any treatment for sleep apnea, including use of continuous positive airway pressure * nyha heart failure, any class * predominantly central apnea * peripheral venous or lymphatic insufficiency * any chronic renal disease * use of diuretics and substances with action in the central or peripheral nervous system such as benzodiazepines, hypnotics, anticonvulsants, antidepressants, appetite suppressants, amphetamines, antiparkinson agents, muscle relaxants, bronchodilators * stroke within 6 months or with incapacitating sequelae * any physical, mental or social condition impairing the ability to participate in the trial

Keywords: sleep apnea treatment sodium-restricted diet diuretic lasilactone
efficacy of pregabalin in the management of chronic uremic pruritus

Conditions: Uremic Pruritus

Summary: uraemic pruritus (up) remains a frequent and distressing problem in patients with advanced or end-stage renal disease. its intensity ranges from sporadic discomfort to complete restlessness during both the day- and night-time and its distribution varies significantly over time. many attempts have been made to relieve this bothersome symptom in affected patients, however with generally limited success. incidence of up varies widely between studies and seems to decline over the last 30 years (from 85% in the 1970s and 50-60% in the 1980s to a 22% in the 2000s) (gunal ai). we use pregabalin for the relief of diabetic neuropathic pain in patients on haemodialysis in our centre. in addition to neuropathic pain, several of our patients have complained of pruritus and after pregabalin treatment, their pruritus has promptly and completely resolved. accordingly, we intend to conduct a double-blind, placebo-controlled, crossover trial to assess the effectiveness of pregabalin in chronic up.


Eligibility criteria:
inclusion criteria: 1. history of pruritus of \>8 weeks duration. 2. severity of pruritus of 7 or more defined by visual analogue scale. 3. no improvement by oral antihistamines or skin moisturizers. 4. discontinuation of any medication with presumed antipruritic effects at least 1 week before the study. 5. negative pregnancy test result for all participating women of childbearing age; exclusion criteria: 1. known allergy to pregabalin 2. any acute illness; 3. liver cirrhosis 4. active dermatological disorder other than up 5. decompensated heart failure; 6. inability to give informed consent; 7. poor compliance.

Keywords: uremic pruritus pregabalin up
first in human study of ibi101 in chinese subjects with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: phase 1a/1b trial to evaluate the tolerability and safety of ibi101 monotherapy or in combination with sintilimab in advanced solid tumor patients.

ibi101 and sintilimab will be administered intravenously on day 1 of every 21-day cycle. the dlt observation period is 21 days starting with the first dose taken on day 1. in the phase ia study, eight dose levels of ibi101 (0.01, 0.1, 0.3, 1, 3, 6, 10 and 15mg/kg) will be tested. in the phase ib study, four dose levels of ibi101 (1, 3, 6 and 10mg/kg), in combination with sintilimab 200mg, will be tested. after completion of the dose escalation phase, two combination dose cohorts (ibi101 3mg/kg and 6mg/kg, in combination with sintilimab 200mg) will be expanded to 10 patients each. ibi101 is a recombinant fully humanized igg1 anti-tumor necrosis factor receptor superfamily member 4 (ox40) monoclonal antibody. sintilimab is a recombinant fully humanized anti-programmed death 1 (pd1) monoclonal antibody.

Eligibility criteria:
inclusion criteria: * patients with locally advanced, recurrent or metastatic solid tumors who have failed standard treatment * 18 to 75 years old * life expectancy ≥ 12 weeks * at least 1 measurable lesion * ecog ps score 0 or 1 * adequate organ and bone marrow function exclusion criteria: * previous exposure to anti-ox40, anti-pd-1, anti-pd-l1, anti-pd-l2 antibody or other immune checkpoint inhibitors * exposure to any other investigational drug in the 4 weeks prior to 1st dose of investigational drug * exposure to anti-tumor agents in the 3 weeks prior to 1st dose of investigational drug * exposure to immunosuppressant in the 3 weeks prior to 1st dose of investigational drug * major surgery in the 4 weeks prior to 1st dose of investigational drug * 30gy radiation in the chest in the 6 months prior to 1st dose of investigational drug * history of autoimmune disease * symptomatic cns metastasis